Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Advance Cancer Treatment
Johnson & Johnson acquires Halda Therapeutics for $3.05B, gaining innovative prostate cancer treatment and platform technology for multiple solid tumors.
/ 913 items
#Healthcare↓
BTIG Starts Coverage on Alto Neuroscience with Buy Rating and $27 Target
BTIG initiates coverage of Alto Neuroscience with a Buy rating and $27 price target, highlighting innovative biomarkers and upcoming data readouts in psychiatric drug development.
LifeMD Offers Lowest Cash-Pay Price for Wegovy & Ozempic at $199/Month
LifeMD now provides the lowest nationwide cash-pay price for Wegovy and Ozempic at $199/month for new patients, supporting more affordable access to GLP-1 weight-loss treatments.
Zymeworks & Jazz Pharmaceuticals Stocks Surge on Positive Cancer Trial Results
Zymeworks jumps 31% and Jazz Pharmaceuticals rises 26% after announcing successful Phase 3 trial results for Ziihera cancer treatment targeting stomach and esophageal cancers.
Repare Therapeutics to Be Acquired by XenoTherapeutics
Repare Therapeutics (RPTX) announces acquisition by XenoTherapeutics for $1.82/share plus contingent value rights, expected to close Q1 2026.
FDA Adds Black Box Warning to Elevidys After Fatal Liver Failures
FDA adds black box warning to Sarepta's (SRPT) Elevidys, limiting use to walking DMD patients after two deaths from liver failure. Stock rose 9% as investors relieved FDA maintained approval for walking patients rather than pulling drug completely.